Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial

HM Kuerer, BD Smith, S Krishnamurthy… - The lancet …, 2022 - thelancet.com
Background Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and
HER2-positive breast cancer yields a pathological complete response in approximately 60 …

Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials

HM Kuerer, MJTFD Vrancken Peeters, DW Rea… - Annals of surgical …, 2017 - Springer
With current advances in neoadjuvant systemic therapy (NST) and improved breast imaging,
the potential of nonoperative therapy for invasive breast cancer has emerged as a viable …

A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - journals.lww.com
Objective: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …

[HTML][HTML] Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges

J Heil, HM Kuerer, A Pfob, G Rauch, HP Sinn… - Annals of …, 2020 - Elsevier
Highlights•Safe past de-escalation treatments.•Surgery after complete response might be
overtreatment.•Biopsies might diagnose response.In patients with operable early breast …

Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: oral presentation at …

J Heil, A Pfob, HP Sinn, G Rauch, P Bach… - Annals of …, 2022 - journals.lww.com
Objective: We evaluated the ability of minimally invasive, image-guided vacuum-assisted
biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B) …

Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit

PER Spronk, JH Volders, P van den Tol… - European Journal of …, 2019 - Elsevier
Introduction NAC has led to an increase in breast conserving surgery (BCS) worldwide. This
study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) and the impact …

Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial

M Golshan, S Loibl, SM Wong, JB Huober… - JAMA …, 2020 - jamanetwork.com
Importance Neoadjuvant systemic therapy (NST) is often administered to enable breast-
conserving therapy (BCT) in stages II to III breast cancer. Objectives To prospectively …

Neoadjuvant chemotherapy in breast cancer: more than just downsizing

MGM Derks, CJH van de Velde - The Lancet Oncology, 2018 - thelancet.com
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) has established a new
milestone in evidencebased treatment for early breast cancer. Through longstanding …

Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery

AB Tadros, WT Yang, S Krishnamurthy… - JAMA …, 2017 - jamanetwork.com
Importance A pathologic complete response (pCR; no invasive or in situ cancer) occurs in
40% to 50% of patients withHER2-positive (HER2+) and triple-negative (TN) breast cancer …

Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a …

AA van Loevezijn, MEM van der Noordaa… - Annals of surgical …, 2021 - Springer
Background The added value of surgery in breast cancer patients with pathological
complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The …